MedTrace Logo

Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk

NCT06316453 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3513

Last updated 2024-03-29

No results posted yet for this study

Summary

This study aims to conduct a 10-year follow-up to assess ASCVD risk in Pakistan among individuals aged 30 years and above without a known history of ASCVD. The focus will be on evaluating ASCVD risk over this specific 10-year timeframe. The study will also validate risk assessment scores for identifying high-risk individuals and examine the incidence rate of ASCVD events during long-term follow-up.

Conditions

  • Atherosclerotic Cardiovascular Diseases (ASCVD)

Interventions

OTHER

Evaluating ASCVD risk over 10 and 30 year and lifetime

Utilizing validated tools such as the Pooled Cohort Equations (PCE) for 10-year ASCVD risk, the 30-year ASCVD risk prediction tool, and lifetime ASCVD risk categories, participants will undergo a thorough risk assessment. This multi-dimensional approach ensures a nuanced understanding of short and long-term cardiovascular risks. Further, The genetic risk for ApoB will be meticulously assessed by genotyping the APOB rs1042031 variant. Subsequently, the calculation of the genetic risk score (GRS) based on risk alleles will provide personalized insight into genetic predispositions related to ASCVD risk. Moreover, Participants will receive personalized management recommendations derived from the ACC/AHA Cardiovascular Risk Assessment Guidelines. These tailored suggestions may encompass dietary programs, lifestyle modifications, and, when indicated, pharmaceutical therapies like statins, aiming to mitigate identified risks effectively

Sponsors & Collaborators

  • University of Karachi

    collaborator OTHER

  • Pakistan Cardiac Society (Heart House)

    collaborator UNKNOWN

  • Advanced Education & Research Center

    lead OTHER

Principal Investigators

  • Tariq Ashraf · National Institute of Cardiovascular Diseases

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06316453 on ClinicalTrials.gov